Normalization of Exhaled Carbonyl Compounds After Lung Cancer Resection

Abstract

BackgroundQuantitative analysis of specific exhaled carbonyl compounds (ECCs) has shown promise for the detection of lung cancer. The purpose of this study is to demonstrate the normalization of ECCs in patients after lung cancer resection.MethodsPatients from a single center gave consent and were enrolled in the study from 2011 onward. Breath analysis was performed on lung cancer patients before and after surgical resection of their tumors. One liter of breath from a single exhalation was collected and evacuated over a silicon microchip. Carbonyls were captured by oximation reaction and analyzed by mass spectrometry. Concentrations of four cancer-specific ECCs were measured and compared by using the Wilcoxon test. A given cancer marker was considered elevated at 1.5 or more standard deviations greater than the mean of the control population.ResultsThere were 34 cancer patients with paired samples and 187 control subjects. The median values after resection were significantly lower for all four ECCs and were equivalent to the control patient values for three of the four ECCs.ConclusionsThe analysis of ECCs demonstrates reduction to the level of control patients after surgical resection for lung cancer. This technology has the potential to be a useful tool to detect disease after lung cancer resection. Continued follow-up will determine whether subsequent elevation of ECCs is indicative of recurrent disease.

Breathprinting and Early Diagnosis of Lung Cancer

“…2,25,38,67 After surgery, breath analysis may serve to determine if and when to perform a follow-up computed tomographic scan or positron-emission tomography. 61,68 When surgery is not indicated and a diagnostic biopsy of a suspected lesion would be hazardous, the e-nose can support the clinical algorithms in establishing malignancy before administering alternative treatments, such as stereotactic body radiation therapy. 2,61,62 Another interesting perspective is represented by the use of the e-nose to identify lung cancer-related genetic mutations and to support Response Evaluation Criteria in Solid Tumors criteria to assess the response to medical treatments.…”

Програмно-Апаратний Комплекс Діагностики Експіраторних Проб Для Виявлення Онкологічних Захворювань

“…Scientists from the USA [18,19,20] began to examine patients with small cells (these could be both malignant and benign tumors) in the lungs. According to the results of the research, they began to use a special silicon processor with a chemically active coating and a mass spectrometer to analyze the condition of patients who have been diagnosed with lung cancer.…”

A novel technology to integrate imaging and clinical markers for non-invasive diagnosis of lung cancer

“…Antibodies in patient blood has also been proposed as a bio-marker for lung cancer in an early stage 21 . Early diagnosis of lung cancer using quantitative analysis of carbonyl VOCs in exhaled breath has been recently reported [22][23][24][25][26] . Analysis of bio-markers is usually quantitative and inexpensive.…”